Takashi Ishikawa
Fujisawa, 2518555, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions.
Journal: Current biology : CB
Published: November 15, 2024
The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys.
Journal: Pharmacology, biochemistry, and behavior
Published: November 14, 2023
Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals.
Journal: Journal of sleep research
Published: November 10, 2022
TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Journal: The Journal of pharmacology and experimental therapeutics
Published: September 15, 2022
Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 22, 2022
Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model.
Journal: Pharmacology, biochemistry, and behavior
Published: July 28, 2022
Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist.
Journal: ACS medicinal chemistry letters
Published: November 08, 2021
TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Journal: Pharmacology, biochemistry, and behavior
Published: September 11, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026